Aditxt, Inc. Files Q1 2025 10-Q Report
Ticker: ADTX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1726711
Sentiment: neutral
Topics: 10-Q, quarterly-report, company-filing
TL;DR
Aditxt Inc. filed its Q1 2025 10-Q. Financials and operations update.
AI Summary
Aditxt, Inc. filed its 10-Q report for the quarterly period ended March 31, 2025. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Mountain View, California.
Why It Matters
This filing provides investors with an update on Aditxt, Inc.'s financial performance and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: low — This is a standard quarterly filing (10-Q) and does not inherently contain new high-risk information.
Key Players & Entities
- Aditxt, Inc. (company) — Registrant
- March 31, 2025 (date) — Quarterly period end date
- Aditx Therapeutics, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Mountain View, CA (location) — Principal executive offices
FAQ
What is the SEC file number for Aditxt, Inc.'s 10-Q filing?
The SEC file number for Aditxt, Inc.'s 10-Q filing is 001-39336.
What is the fiscal year end for Aditxt, Inc.?
Aditxt, Inc.'s fiscal year ends on December 31.
When was Aditxt, Inc. formerly known as ADiTx Therapeutics, Inc.?
Aditxt, Inc. was formerly known as ADiTx Therapeutics, Inc. with a date of name change on 20171229.
What is the SIC code for Aditxt, Inc.?
The Standard Industrial Classification (SIC) code for Aditxt, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the business address of Aditxt, Inc.?
The business address of Aditxt, Inc. is 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Aditxt, Inc. (ADTX).